
For more than two decades, the Argentine-trained virologist has run TechnoVax on one durable idea: build convincing copies of viruses, leave out the genetic machinery, and make the platform do more than one job.
TechnoVax has spent two decades making convincing copies of dangerous viruses - minus the genes that make them dangerous. Its science has attracted roughly $10 million in federal awards; the harder experiment is turning a tiny lab's preclinical wins into a product people can actually receive.